DOP2021000165A - Anticuerpos anti-trem1 y métodos relacionados - Google Patents
Anticuerpos anti-trem1 y métodos relacionadosInfo
- Publication number
- DOP2021000165A DOP2021000165A DO2021000165A DO2021000165A DOP2021000165A DO P2021000165 A DOP2021000165 A DO P2021000165A DO 2021000165 A DO2021000165 A DO 2021000165A DO 2021000165 A DO2021000165 A DO 2021000165A DO P2021000165 A DOP2021000165 A DO P2021000165A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- trem1
- related methods
- trem1 antibodies
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802161P | 2019-02-06 | 2019-02-06 | |
| US201962889994P | 2019-08-21 | 2019-08-21 | |
| PCT/US2020/016949 WO2020163564A2 (en) | 2019-02-06 | 2020-02-06 | Anti-trem1 antibodies and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2021000165A true DOP2021000165A (es) | 2021-09-30 |
Family
ID=71947128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2021000165A DOP2021000165A (es) | 2019-02-06 | 2021-08-06 | Anticuerpos anti-trem1 y métodos relacionados |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20250179185A1 (https=) |
| EP (1) | EP3921344A4 (https=) |
| JP (2) | JP7492522B2 (https=) |
| KR (1) | KR20210126638A (https=) |
| CN (1) | CN113748132B (https=) |
| AU (1) | AU2020218525A1 (https=) |
| BR (1) | BR112021015479A2 (https=) |
| CA (1) | CA3128053A1 (https=) |
| CL (1) | CL2021002075A1 (https=) |
| CO (1) | CO2021010887A2 (https=) |
| CR (1) | CR20210462A (https=) |
| DO (1) | DOP2021000165A (https=) |
| IL (1) | IL284818A (https=) |
| MX (1) | MX2021009500A (https=) |
| PE (1) | PE20212269A1 (https=) |
| PH (1) | PH12021551903A1 (https=) |
| SG (1) | SG11202108570SA (https=) |
| TW (1) | TWI870382B (https=) |
| WO (1) | WO2020163564A2 (https=) |
| ZA (1) | ZA202210284B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260017009A (ko) | 2023-04-21 | 2026-02-04 | 셀시우스 테라퓨틱스, 인코포레이티드 | 항-trem1 항체 제제, 조성물 및 이의 용도 |
| WO2025201129A1 (zh) * | 2024-03-28 | 2025-10-02 | 北京丹序生物制药有限公司 | 一种抗触发受体-1抗体或其抗原结合片段及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150376294A1 (en) * | 2012-12-03 | 2015-12-31 | Rigshospitalet | Anti-pad2 antibodies and treatment of autoimmune diseases |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| DK3653221T5 (da) * | 2015-02-19 | 2024-08-26 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| WO2017127933A1 (en) * | 2016-01-29 | 2017-08-03 | The Governing Council Of The University Of Toronto | Frizzled protein-binding agents and methods of use thereof |
| WO2017152102A2 (en) * | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
| KR20230119259A (ko) * | 2016-04-15 | 2023-08-16 | 이뮤넥스트, 인크. | 항-인간 vista 항체 및 이의 용도 |
-
2020
- 2020-02-06 KR KR1020217028210A patent/KR20210126638A/ko active Pending
- 2020-02-06 SG SG11202108570SA patent/SG11202108570SA/en unknown
- 2020-02-06 BR BR112021015479A patent/BR112021015479A2/pt unknown
- 2020-02-06 WO PCT/US2020/016949 patent/WO2020163564A2/en not_active Ceased
- 2020-02-06 EP EP20752176.6A patent/EP3921344A4/en active Pending
- 2020-02-06 CA CA3128053A patent/CA3128053A1/en active Pending
- 2020-02-06 CR CR20210462A patent/CR20210462A/es unknown
- 2020-02-06 CN CN202080027026.9A patent/CN113748132B/zh active Active
- 2020-02-06 PE PE2021001282A patent/PE20212269A1/es unknown
- 2020-02-06 JP JP2021545857A patent/JP7492522B2/ja active Active
- 2020-02-06 AU AU2020218525A patent/AU2020218525A1/en active Pending
- 2020-02-06 MX MX2021009500A patent/MX2021009500A/es unknown
- 2020-02-06 TW TW109103757A patent/TWI870382B/zh active
- 2020-02-06 PH PH1/2021/551903A patent/PH12021551903A1/en unknown
-
2021
- 2021-07-13 IL IL284818A patent/IL284818A/en unknown
- 2021-08-05 CL CL2021002075A patent/CL2021002075A1/es unknown
- 2021-08-06 DO DO2021000165A patent/DOP2021000165A/es unknown
- 2021-08-18 CO CONC2021/0010887A patent/CO2021010887A2/es unknown
-
2022
- 2022-09-16 ZA ZA2022/10284A patent/ZA202210284B/en unknown
-
2024
- 2024-05-17 JP JP2024080881A patent/JP7759996B2/ja active Active
- 2024-07-09 US US18/767,771 patent/US20250179185A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113748132A (zh) | 2021-12-03 |
| CL2021002075A1 (es) | 2022-04-01 |
| EP3921344A4 (en) | 2022-10-12 |
| JP2024105632A (ja) | 2024-08-06 |
| CO2021010887A2 (es) | 2021-09-09 |
| IL284818A (en) | 2021-08-31 |
| KR20210126638A (ko) | 2021-10-20 |
| CN113748132B (zh) | 2026-01-27 |
| PH12021551903A1 (en) | 2022-08-01 |
| SG11202108570SA (en) | 2021-09-29 |
| JP7492522B2 (ja) | 2024-05-29 |
| JP2022523145A (ja) | 2022-04-21 |
| AU2020218525A1 (en) | 2021-09-23 |
| TW202037613A (zh) | 2020-10-16 |
| EP3921344A2 (en) | 2021-12-15 |
| WO2020163564A3 (en) | 2020-09-24 |
| PE20212269A1 (es) | 2021-11-30 |
| WO2020163564A2 (en) | 2020-08-13 |
| CR20210462A (es) | 2021-12-13 |
| BR112021015479A2 (pt) | 2021-12-28 |
| TWI870382B (zh) | 2025-01-21 |
| MX2021009500A (es) | 2021-09-08 |
| US20250179185A1 (en) | 2025-06-05 |
| JP7759996B2 (ja) | 2025-10-24 |
| CA3128053A1 (en) | 2020-08-13 |
| ZA202210284B (en) | 2023-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000128A (es) | Anticuerpos anti-trem2 y métodos relacionados | |
| UY40829A (es) | Anticuerpos anti-phf-tau y sus usos | |
| PH12021551426A1 (en) | Humanized anti-human-pd-1 antibody | |
| MX2021011696A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
| MX2021014448A (es) | Modulacion de celulas mieloides estimulantes y no estimulantes. | |
| MX2024007724A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado | |
| MX374810B (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos | |
| MX2017012939A (es) | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. | |
| ZA201904218B (en) | Anti¿ccr7 antibody drug conjugates | |
| BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
| AR093357A1 (es) | Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer | |
| MX2024010984A (es) | Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control. | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| DOP2021000165A (es) | Anticuerpos anti-trem1 y métodos relacionados | |
| MX2024006295A (es) | Anticuerpos monoclonales de adn dirigidos al virus de la influenza. | |
| MX2020003806A (es) | Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. | |
| AR118028A1 (es) | Anticuerpos anti-trem1 y métodos relacionados | |
| EA202091458A1 (ru) | Анти-trem2 антитела и связанные с ними способы | |
| EA202090201A3 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
| AR106284A1 (es) | Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19 | |
| AR106319A1 (es) | Proteínas de unión a antígeno que activan el receptor de leptina |